And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.
What are the recommendations for managing anemia in patients receiving olaparib?
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Veliparib added to chemotherapy, continued as maintenance tx prolongs progression-free survival.
Correlation moderately attenuated after adjustment for health and ovarian cancer risk factors.